A Board Member Bought Shares of JPMorgan Chase

Page 1 of 2

According to a filing with the SEC, Timothy Flynn, a member of the Board of Directors at JPMorgan Chase & Co. (NYSE:JPM), directly purchased about 6,800 shares of the bank’s stock on January 29th at an average price of $46.93 per share. This roughly $320,000 investment brought Flynn’s total holdings of JPM to almost 15,000 shares. We track insider purchases because they tend to be bullish signals, though average outperformance of the market is very slight when only one insider is buying the stock (read more about studies on insider trading). Interestingly, earlier in January we had reported on an insider purchase at Bank of America Corp (NYSE:BAC). See our coverage of an insider purchase at Bank of America. We’d wonder if these buys might be interpreted as more general optimism on the large banks.

In the fourth quarter of 2012, JPMorgan Chase & co. experienced double-digit growth rates of both revenue and net income versus a year earlier. In fact, revenue was up almost 20% while earnings surged over 50%. While these growth rates are of course not sustainable, they suggest that JPMorgan Chase’s business is performing well in the current financial environment. In fact, given the current stock price, the bank does not really need to deliver any further improvements in order to be a good value: the trailing P/E multiple is only 9. With the rise in its stock price (up 25% in the last year, despite the London Whale fiasco), JPMorgan Chase’s discount to book value has narrowed and the current P/B ratio is 0.9. As a result JPMorgan Chase & Co. appears to be a good value and we can see why an insider would be buying the stock.


JPMorgan Chase, along with Bank of America, Citigroup Inc. (NYSE:C), and Wells Fargo & Company (NYSE:WFC) was one of the most popular stocks among hedge funds in the third quarter of 2012 (see the full top ten list). Billionaire Ken Fisher’s Fisher Asset Management more than doubled the size of its position during the quarter and closed September with over 13 million shares in its portfolio (check out Fisher’s stock picks). AQR Capital Management, which is managed by Cliff Asness, reported a position of 4.2 million shares in its own 13F filing (find Asness’s favorite stocks).

How does JPMorgan Chase compare to these peers as a value investment?

Page 1 of 2

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!